Growth Metrics

Ultragenyx Pharmaceutical (RARE) Assets Average (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Assets Average for 10 consecutive years, with $1.4 billion as the latest value for Q4 2025.

  • Quarterly Assets Average fell 10.49% to $1.4 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.4 billion through Dec 2025, down 10.49% year-over-year, with the annual reading at $1.5 billion for FY2025, 1.37% up from the prior year.
  • Assets Average for Q4 2025 was $1.4 billion at Ultragenyx Pharmaceutical, up from $1.2 billion in the prior quarter.
  • The five-year high for Assets Average was $1.7 billion in Q1 2021, with the low at $1.2 billion in Q3 2025.
  • Average Assets Average over 5 years is $1.4 billion, with a median of $1.5 billion recorded in 2022.
  • The sharpest move saw Assets Average soared 41.74% in 2021, then dropped 20.91% in 2025.
  • Over 5 years, Assets Average stood at $1.5 billion in 2021, then rose by 5.21% to $1.6 billion in 2022, then fell by 13.74% to $1.4 billion in 2023, then grew by 11.44% to $1.5 billion in 2024, then fell by 10.49% to $1.4 billion in 2025.
  • According to Business Quant data, Assets Average over the past three periods came in at $1.4 billion, $1.2 billion, and $1.3 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.